Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study

被引：5
作者：
Song, Yeo-Jin [1 ,2 ]
Cho, Soo-Kyung [1 ,2 ]
Kim, Hyoungyoung [1 ,2 ]
Kim, Hye Won [2 ]
Nam, Eunwoo [2 ]
Jeon, Ja-Young [3 ]
Yoo, Hyun-Jeong [3 ]
Choi, Chan-Bum [1 ,2 ]
Kim, Tae-Hwan [1 ,2 ]
Jun, Jae-Bum [1 ,2 ]
Bae, Sang-Cheol [1 ,2 ]
Yoo, Dae Hyun [1 ,2 ]
Sung, Yoon-Kyoung [1 ,2 ]
机构：
[1] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, 222-1 Wangsimni Ro, Seoul 04763, South Korea
[2] Hanyang Univ, Inst Rheumatol Res, Seoul, South Korea
[3] Pfizer Pharmaceut Korea Ltd, Seoul, South Korea
来源：
SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期
关键词：
MODIFYING ANTIRHEUMATIC DRUGS; UNITED-STATES; VARICELLA; VIRUS; METHOTREXATE; INFECTIONS;
D O I：
10.1038/s41598-023-33718-7
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
We aimed to determine the risk of herpes zoster (HZ) in Korean rheumatoid arthritis (RA) patients on tofacitinib compared with tumor necrosis factor inhibitor (TNFi) treatment. From the prospective cohorts of RA patients who started tofacitinib or TNFi in an academic referral hospital in Korea, patients who started tofacitinib between March 2017 and May 2021 and those who started TNFi between July 2011 and May 2021 were included. Baseline characteristics of tofacitinib and TNFi users were balanced through inverse probability of treatment weighting (IPTW) using the propensity score including age, disease activity of RA and medication use. The incidence rate of HZ in each group and incidence rate ratio (IRR) were calculated. A total of 912 patients were included: 200 tofacitinib and 712 TNFi users. There were 20 cases of HZ among tofacitinib users and 36 among TNFi users during observation period of 331.4 person-years (PYs) and 1950.7 PYs, respectively. In IPTW analysis with a balanced sample, IRR of HZ was 8.33 (95% confidence interval 3.05-22.76). Tofacitinib use increased the risk of HZ compared with TNFi in Korean patients with RA, but the rate of serious HZ or permanent discontinuation of tofacitinib due to HZ event was low.
引用
收藏
页数：8
相关论文
共 27 条
[1]   Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis [J].
Almanzar, Giovanni ;
Kienle, Felix ;
Schmalzing, Marc ;
Maas, Anna ;
Tony, Hans-Peter ;
Prelog, Martina .
RHEUMATOLOGY, 2019, 58 (11) :2051-2060
[2]   Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses [J].
Bing, Nan ;
Zhou, Huanyu ;
Chen, Xing ;
Hirose, Tomohiro ;
Kochi, Yuta ;
Tsuchida, Yumi ;
Ishigaki, Kazuyoshi ;
Sumitomo, Shuji ;
Fujio, Keishi ;
Zhang, Baohong ;
Valdez, Hernan ;
Vincent, Michael S. ;
Martin, David ;
Clark, James D. .
ARTHRITIS & RHEUMATOLOGY, 2021, 73 (07) :1155-1166
[3]   Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA) [J].
Cho, Soo-Kyung ;
Kim, Dam ;
Jun, Jae-Bum ;
Bae, Sang-Cheol ;
Sung, Yoon-Kyoung .
RHEUMATOLOGY INTERNATIONAL, 2013, 33 (01) :93-102
[4]   Disease burden of herpes zoster in Korea [J].
Choi, Won Suk ;
Noh, Ji Yun ;
Huh, Joong Yeon ;
Jo, Yu Mi ;
Lee, Jacob ;
Song, Joon Young ;
Kim, Woo Joo ;
Cheong, Hee Jin .
JOURNAL OF CLINICAL VIROLOGY, 2010, 47 (04) :325-329
[5]   Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids [J].
Curtis, Jeffrey R. ;
Xie, Fenglong ;
Yang, Shuo ;
Bernatsky, Sasha ;
Chen, Lang ;
Yun, Huifeng ;
Winthrop, Kevin .
ARTHRITIS CARE & RESEARCH, 2019, 71 (09) :1249-1254
[6]   Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis [J].
Curtis, Jeffrey R. ;
Xie, Fenglong ;
Yun, Huifeng ;
Bernatsky, Sasha ;
Winthrop, Kevin L. .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (10) :1843-1847
[7]   Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD [J].
Furer, Victoria ;
Rondaan, Christien ;
Heijstek, Marloes ;
van Assen, Sander ;
Bijl, Marc ;
Agmon-Levin, Nancy ;
Breedveld, Ferdinand C. ;
D'Amelio, Raffaele ;
Dougados, Maxime ;
Kapetanovic, Meliha Crnkic ;
van Laar, Jacob M. ;
de Thurah, Annette Ladefoged ;
Landewe, Robert ;
Molto, Anna ;
Mueller-Ladner, Ulf ;
Schreiber, Karen ;
Smolar, Leo ;
Walker, Jim ;
Warnatz, Klaus ;
Wulffraat, Nico M. ;
Elkayam, Ori .
RMD OPEN, 2019, 5 (02)
[8]   Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study [J].
Jeong, Seogsong ;
Choi, Seulggie ;
Park, Sang Min ;
Kim, Jinseok ;
Ghang, Byeongzu ;
Lee, Eun Young .
ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
[9]   Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea [J].
Kang, Cheol-In ;
Choi, Chang-Min ;
Park, Tae-Sung ;
Lee, Dong-Jun ;
Oh, Myoung-don ;
Choe, Kang-Won .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (03) :245-247
[10]   Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry [J].
Kremer, Joel M. ;
Bingham, Clifton O. ;
Cappelli, Laura C. ;
Greenberg, Jeffrey D. ;
Madsen, Ann M. ;
Geier, Jamie ;
Rivas, Jose L. ;
Onofrei, Alina M. ;
Barr, Christine J. ;
Pappas, Dimitrios A. ;
Litman, Heather J. ;
Dandreo, Kimberly J. ;
Shapiro, Andrea B. ;
Connell, Carol A. ;
Kavanaugh, Arthur .
ACR OPEN RHEUMATOLOGY, 2021, 3 (03) :173-184
123